-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News, April 19th.
Today, the fifth batch of centralized procurement documents was released, containing a total of 60 varieties and 207 specifications, including cancer chemotherapy drugs, digestive preparations, antibiotics, respiratory, inhalation preparations, contrast agents, and diabetes drugs.
, Auxiliary medications, ophthalmology-related medications, antiviral medications, etc.
Among them, 30 injections are included.
The fifth batch of centralized procurement is also the largest and the largest number of products so far.
Today, the fifth batch of centralized procurement documents was released, containing a total of 60 varieties and 207 specifications, including cancer chemotherapy drugs, digestive preparations, antibiotics, respiratory, inhalation preparations, contrast agents, and diabetes drugs.
, Auxiliary medications, ophthalmology-related medications, antiviral medications, etc.
Among them, 30 injections are included.
The fifth batch of centralized procurement is also the largest and the largest number of products so far.
In terms of the specific implementation time of the fifth batch of centralized procurement, the document shows that before 24:00 on April 18 this year, all provinces can conduct volume reporting operation tests through the system, and the volume reporting will be officially launched on April 19, and each province chooses medical institutions to report directly or Provincial-level reporting method, fill in the pre-purchasing quantity of relevant drugs , and complete it before 24:00 on April 30.
All provinces will complete the review of pre-purchasing quantities of medicines before 17:00 on May 12, export and print them together, affix the official seal of the Provincial Medical Insurance Bureau, and submit the electronic files and scanned copies to the Joint Procurement Office by the system.
All provinces will complete the review of pre-purchasing quantities of medicines before 17:00 on May 12, export and print them together, affix the official seal of the Provincial Medical Insurance Bureau, and submit the electronic files and scanned copies to the Joint Procurement Office by the system.
There was also news in the industry before that, the fifth batch of centralized procurement will be carried out in May-June.
01 Jicai has tilted injection
According to the incomplete statistics of the E medicine manager, 3 of 37 varieties have been reviewed, 4 of 8 varieties have been reviewed, 5 of 8 varieties have been reviewed, 6 of 5 varieties have been reviewed, and 9 of 1 variety have been reviewed.
13 varieties have been reviewed.
There are 13 companies that have reviewed rivaroxaban tablets, 9 companies have reviewed esomeprazole sodium for injection, 6 companies have reviewed levofloxacin sodium chloride injection, ceftriaxone sodium for injection, ceftazidime for injection 5 reviews.
13 varieties have been reviewed.
There are 13 companies that have reviewed rivaroxaban tablets, 9 companies have reviewed esomeprazole sodium for injection, 6 companies have reviewed levofloxacin sodium chloride injection, ceftriaxone sodium for injection, ceftazidime for injection 5 reviews.
It can be seen from the list of the fifth batch that the national centralized procurement has gradually tilted towards the field of injections, with 30 injection formulations accounting for 50% of all varieties.
Compared with the fourth batch of centralized procurement a few months ago, there are only 8 types of injections, accounting for 19%.
Compared with the fourth batch of centralized procurement a few months ago, there are only 8 types of injections, accounting for 19%.
Among the types of injections, antibiotics account for a relatively high proportion, including cefuroxime, ceftriaxone, ceftazidime, ceftazolin, azithromycin, etc.
; oncology drugs include gemcitabine, paclitaxel, oxaliplatin, docetaxel, etc.
; and diabetes The drug saxagliptin, esomeprazole (esomeprazole) in the digestive field, budesonide inhalation in the respiratory field and other large varieties.
; oncology drugs include gemcitabine, paclitaxel, oxaliplatin, docetaxel, etc.
; and diabetes The drug saxagliptin, esomeprazole (esomeprazole) in the digestive field, budesonide inhalation in the respiratory field and other large varieties.
Data show that in 2019, China's injection drug market has exceeded 600 billion yuan.
From the first to fifth batch of centralized procurement varieties, with the in-depth evaluation of the consistency of injections, the main force of centralized procurement across the country will further tilt toward the varieties of injections.
From the first to fifth batch of centralized procurement varieties, with the in-depth evaluation of the consistency of injections, the main force of centralized procurement across the country will further tilt toward the varieties of injections.
02 Foreign-invested AZ is the most shortlisted, and domestic-funded leaders play the leading role
From the perspective of the original research companies involved, AstraZeneca is the foreign-funded company with the largest variety of finalists in this round, involving 6 products, esomeprazole (esomeprazole) injection, isosorbide mononitrate sustained-release and controlled-release Dosage form, saxagliptin oral constant-release dosage form, oral bicalutamide oral constant-release dosage form for injection, budesonide inhalation, and metoprolol oral regular-release dosage form are shortlisted.
Among them, esomeprazole (esomeprazole) injection has been evaluated by 8 companies in addition to the original research, including well-known domestic companies such as Chia Tai Tianqing, Haisco, Osaikon; Isosorbide mononitrate sustained release Controlled-release dosage forms have also been reviewed by five companies including Qilu and Lepu; the competition for oral regular-release dosage forms of saxagliptin is more intense, with Qilu, Zhengda Tianqing, Hausen, and Osaikang all eyeing them.
Among them, esomeprazole (esomeprazole) injection has been evaluated by 8 companies in addition to the original research, including well-known domestic companies such as Chia Tai Tianqing, Haisco, Osaikon; Isosorbide mononitrate sustained release Controlled-release dosage forms have also been reviewed by five companies including Qilu and Lepu; the competition for oral regular-release dosage forms of saxagliptin is more intense, with Qilu, Zhengda Tianqing, Hausen, and Osaikang all eyeing them.
The number of products shortlisted by Pfizer is second only to AstraZeneca, reaching five.
Contains azithromycin injection; fluconazole sodium chloride injection, glipizide sustained-release and controlled-release dosage form, linezolid glucose injection, and misoprostol oral regular-release dosage form.
Many products will face the impact of centralized procurement from Kelun, Hausen, Yangtze River and Renfu.
Contains azithromycin injection; fluconazole sodium chloride injection, glipizide sustained-release and controlled-release dosage form, linezolid glucose injection, and misoprostol oral regular-release dosage form.
Many products will face the impact of centralized procurement from Kelun, Hausen, Yangtze River and Renfu.
GSK has three shortlisted products, dutasteride soft capsule, cefuroxime injection, and ceftazidime injection.
Among them, ceftazidime injection has been evaluated by Qilu, Hailing Chemical, Chengdu Beite, Yangtze River, and Hanmi Pharmaceutical Co.
, Ltd.
Among them, ceftazidime injection has been evaluated by Qilu, Hailing Chemical, Chengdu Beite, Yangtze River, and Hanmi Pharmaceutical Co.
, Ltd.
Sanofi's oncology product docetaxel injection and oxaliplatin injection are shortlisted, among which docetaxel injection faces the 5+1 competition of Hengrui, Yangtze River, Qilu, Zhengda Tianqing, and Huiyu.
Novartis, Boehringer Ingelheim, Fresenius Kabi and other foreign companies have two products shortlisted; Bayer and Daiichi Sankyo also each have one product shortlisted.
Novartis, Boehringer Ingelheim, Fresenius Kabi and other foreign companies have two products shortlisted; Bayer and Daiichi Sankyo also each have one product shortlisted.
In the past four batches and five rounds of centralized procurement, the original research pharmaceutical companies performed differently, but mainly focused on maintaining the original price system.
However, there are also companies that choose to directly compete with domestic generic drug companies and drastically cut prices.
For example, AstraZeneca’s Iressa in 4+7 volume procurement, Bayer’s Bayer in the second batch of centralized procurement, the fourth batch Propofol medium/long-chain fat emulsion injection from Fresenius Kabi in the collection.
However, there are also companies that choose to directly compete with domestic generic drug companies and drastically cut prices.
For example, AstraZeneca’s Iressa in 4+7 volume procurement, Bayer’s Bayer in the second batch of centralized procurement, the fourth batch Propofol medium/long-chain fat emulsion injection from Fresenius Kabi in the collection.
In terms of domestic pharmaceutical companies, China Biopharmaceutical's Chia Tai Tianqing, Chia Tai Fenghai, Beijing Tide and other products have accumulated more than 10 shortlisted products.
They are still the "big players" in this centralized procurement, followed by domestic generic drug giants Qilu, Yangtze River was also shortlisted for 9 products.
As the domestic infusion leader, Kelun has 8 injection products entering the market this time; traditional major manufacturers such as Hengrui, CSPC, Xinlitai, and Haisco have 3 products entering.
They are still the "big players" in this centralized procurement, followed by domestic generic drug giants Qilu, Yangtze River was also shortlisted for 9 products.
As the domestic infusion leader, Kelun has 8 injection products entering the market this time; traditional major manufacturers such as Hengrui, CSPC, Xinlitai, and Haisco have 3 products entering.
Judging from the results of the previous rounds of centralized procurement, drug prices fell by more than 50% on average, and the highest drop was more than 90%.
After this time, the market structure of a large number of varieties will change.
After this time, the market structure of a large number of varieties will change.
03Four major cephalosporin antibiotics in the list of basic medicines
In the current base drug list, there are a total of four cephalosporin antibiotic products for injection-cefazolin injection, cefuroxime sodium injection, ceftriaxone injection, and ceftazidime injection.
No one is spared in the fifth batch of collective procurement reports.
No one is spared in the fifth batch of collective procurement reports.
Ceftazidime injection and ceftriaxone injection have each entered the market with 6 companies.
Six companies including GSK, Qilu, Yangtze River, Hailing Chemical, Chengdu Beite, and Hanmi Pharmaceutical Co.
, Ltd.
compete for ceftazidime injection; Roche, Qilu, CSPC, Kelun, Jincheng Jinsu, and Runze will be on the ceftriaxone injection track A showdown.
Six companies including GSK, Qilu, Yangtze River, Hailing Chemical, Chengdu Beite, and Hanmi Pharmaceutical Co.
, Ltd.
compete for ceftazidime injection; Roche, Qilu, CSPC, Kelun, Jincheng Jinsu, and Runze will be on the ceftriaxone injection track A showdown.
The competitive landscape of cefuroxime injection is relatively sluggish, and it is in the three-part world of GSK, Whitison, and Runze Pharmaceutical.
On January 21 this year, Cefazolin for injection has just ushered in the first over-reviewed company, Jincheng Pharmaceutical .
Data show that the sales of cefazolin for injection in 2020 will be nearly 4 billion yuan.
Data show that the sales of cefazolin for injection in 2020 will be nearly 4 billion yuan.
According to NMPA data, there are currently 16 cephalosporin products in China that have approved generic drugs.
Among the first four batches of centralized procurement, 7 products have been included in centralized procurement.
Among the 9 varieties not included in the collection, there are 8 injection varieties.
The blockbuster cephalosporin products included in the four basic medicines in the centralized procurement in one breath have a large variety with billions of sales.
After entering the centralized procurement, the market may usher in a wave of increased volume.
Among the first four batches of centralized procurement, 7 products have been included in centralized procurement.
Among the 9 varieties not included in the collection, there are 8 injection varieties.
The blockbuster cephalosporin products included in the four basic medicines in the centralized procurement in one breath have a large variety with billions of sales.
After entering the centralized procurement, the market may usher in a wave of increased volume.
04 Biosimilar drugs, Chinese medicine suspended
Judging from the fifth batch of centralized procurement catalogs, insulin, biosimilar drugs, and proprietary Chinese medicines that the industry continues to pay attention to are still not involved, which has made many companies let go of their suspicions.
However, judging from the "Opinions on Promoting the Normalized and Institutionalized Development of Centralized and Volume pharmnet.
com.
cn/news/yyzb/" target="_blank">Procurement of Drugs" issued by the State Council in January this year , the document proposes that unreviewed varieties, proprietary Chinese medicines, and biosimilars will be included in centralized drug procurement.
com.
cn/news/yyzb/" target="_blank">Procurement of Drugs" issued by the State Council in January this year , the document proposes that unreviewed varieties, proprietary Chinese medicines, and biosimilars will be included in centralized drug procurement.
In addition, on March 5th, the National Medical Insurance Bureau and the Department of Recruitment and Procurement and representatives of 11 provinces and cities including Tianjin, Shanghai, Chongqing and other joint procurement offices organized a drug centralized procurement work conference in Nanjing to study and carry out special drug procurement and study national procurement products with large quantities.
After the expiration, the contract renewal work will improve the selection rules of the national drug collection plan.
After the expiration, the contract renewal work will improve the selection rules of the national drug collection plan.
According to the normalized deployment of "centralized procurement twice a year", although biosimilar drugs and proprietary Chinese medicines have not yet appeared in the fifth batch of centralized procurement, whether it is the information released by the medical insurance bureau’s symposium or the normalized collection of the State Council From the perspective of opinions, it will be sooner or later that these types of products will be included in centralized procurement.
Medical Network News, April 19th.
Today, the fifth batch of centralized procurement documents was released, containing a total of 60 varieties and 207 specifications, including cancer chemotherapy drugs, digestive preparations, antibiotics, respiratory, inhalation preparations, contrast agents, and diabetes drugs.
, Auxiliary medications, ophthalmology-related medications, antiviral medications, etc.
Among them, 30 injections are included.
The fifth batch of centralized procurement is also the largest and the largest number of products so far.
Today, the fifth batch of centralized procurement documents was released, containing a total of 60 varieties and 207 specifications, including cancer chemotherapy drugs, digestive preparations, antibiotics, respiratory, inhalation preparations, contrast agents, and diabetes drugs.
, Auxiliary medications, ophthalmology-related medications, antiviral medications, etc.
Among them, 30 injections are included.
The fifth batch of centralized procurement is also the largest and the largest number of products so far.
In terms of the specific implementation time of the fifth batch of centralized procurement, the document shows that before 24:00 on April 18 this year, all provinces can conduct volume reporting operation tests through the system, and the volume reporting will be officially launched on April 19, and each province chooses medical institutions to report directly or Provincial-level reporting method, fill in the pre-purchasing quantity of relevant drugs , and complete it before 24:00 on April 30.
All provinces will complete the review of pre-purchasing quantities of medicines before 17:00 on May 12, export and print them together, affix the official seal of the Provincial Medical Insurance Bureau, and submit the electronic files and scanned copies to the Joint Procurement Office by the system.
All provinces will complete the review of pre-purchasing quantities of medicines before 17:00 on May 12, export and print them together, affix the official seal of the Provincial Medical Insurance Bureau, and submit the electronic files and scanned copies to the Joint Procurement Office by the system.
There was also news in the industry before that, the fifth batch of centralized procurement will be carried out in May-June.
01 Jicai has tilted injection
According to the incomplete statistics of the E medicine manager, 3 of 37 varieties have been reviewed, 4 of 8 varieties have been reviewed, 5 of 8 varieties have been reviewed, 6 of 5 varieties have been reviewed, and 9 of 1 variety have been reviewed.
13 varieties have been reviewed.
There are 13 companies that have reviewed rivaroxaban tablets, 9 companies have reviewed esomeprazole sodium for injection, 6 companies have reviewed levofloxacin sodium chloride injection, ceftriaxone sodium for injection, ceftazidime for injection 5 reviews.
13 varieties have been reviewed.
There are 13 companies that have reviewed rivaroxaban tablets, 9 companies have reviewed esomeprazole sodium for injection, 6 companies have reviewed levofloxacin sodium chloride injection, ceftriaxone sodium for injection, ceftazidime for injection 5 reviews.
It can be seen from the list of the fifth batch that the national centralized procurement has gradually tilted towards the field of injections, with 30 injection formulations accounting for 50% of all varieties.
Compared with the fourth batch of centralized procurement a few months ago, there are only 8 types of injections, accounting for 19%.
Compared with the fourth batch of centralized procurement a few months ago, there are only 8 types of injections, accounting for 19%.
Among the types of injections, antibiotics account for a relatively high proportion, including cefuroxime, ceftriaxone, ceftazidime, ceftazolin, azithromycin, etc.
; oncology drugs include gemcitabine, paclitaxel, oxaliplatin, docetaxel, etc.
; and diabetes The drug saxagliptin, esomeprazole (esomeprazole) in the digestive field, budesonide inhalation in the respiratory field and other large varieties.
; oncology drugs include gemcitabine, paclitaxel, oxaliplatin, docetaxel, etc.
; and diabetes The drug saxagliptin, esomeprazole (esomeprazole) in the digestive field, budesonide inhalation in the respiratory field and other large varieties.
Data show that in 2019, China's injection drug market has exceeded 600 billion yuan.
From the first to fifth batch of centralized procurement varieties, with the in-depth evaluation of the consistency of injections, the main force of centralized procurement across the country will further tilt toward the varieties of injections.
From the first to fifth batch of centralized procurement varieties, with the in-depth evaluation of the consistency of injections, the main force of centralized procurement across the country will further tilt toward the varieties of injections.
02 Foreign-invested AZ is the most shortlisted, and domestic-funded leaders play the leading role
，，6，（）、、、、、。，（），8，、、；、5；，、、、。
，5。；、、、。、、、。
GSK、、，、、、、。
，、、、、5+1。、、2；、1。
，，。、，4+7、，/。
，、、10，“”，、9，，8；、、、3。
，50%，90%。，。
03
，——、、、。，。
6。GSK、、、、、；、、、、、。
，GSK、、。
121，，。，202040。
NMPA，16。，7。9，8。4，，，。
04 、
，、，。
1《pharmnet.
com.
cn/news/yyzb/" target="_blank">》，、。
com.
cn/news/yyzb/" target="_blank">》，、。
，35、、11，，，。
According to the normalized deployment of "centralized procurement twice a year", although biosimilar drugs and proprietary Chinese medicines have not yet appeared in the fifth batch of centralized procurement, whether it is the information released by the medical insurance bureau’s symposium or the normalized collection of the State Council From the perspective of opinions, it will be sooner or later that these types of products will be included in centralized procurement.
Medical Network News, April 19th.
Today, the fifth batch of centralized procurement documents was released, containing a total of 60 varieties and 207 specifications, including cancer chemotherapy drugs, digestive preparations, antibiotics, respiratory, inhalation preparations, contrast agents, and diabetes drugs.
, Auxiliary medications, ophthalmology-related medications, antiviral medications, etc.
Among them, 30 injections are included.
The fifth batch of centralized procurement is also the largest and the largest number of products so far.
Today, the fifth batch of centralized procurement documents was released, containing a total of 60 varieties and 207 specifications, including cancer chemotherapy drugs, digestive preparations, antibiotics, respiratory, inhalation preparations, contrast agents, and diabetes drugs.
, Auxiliary medications, ophthalmology-related medications, antiviral medications, etc.
Among them, 30 injections are included.
The fifth batch of centralized procurement is also the largest and the largest number of products so far.
In terms of the specific implementation time of the fifth batch of centralized procurement, the document shows that before 24:00 on April 18 this year, all provinces can conduct volume reporting operation tests through the system, and the volume reporting will be officially launched on April 19, and each province chooses medical institutions to report directly or Provincial-level reporting method, fill in the pre-purchasing quantity of relevant drugs , and complete it before 24:00 on April 30.
All provinces will complete the review of pre-purchasing quantities of medicines before 17:00 on May 12, export and print them together, affix the official seal of the Provincial Medical Insurance Bureau, and submit the electronic files and scanned copies to the Joint Procurement Office by the system.
Medicine, medicine, medicineAll provinces will complete the review of pre-purchasing quantities of medicines before 17:00 on May 12, export and print them together, affix the official seal of the Provincial Medical Insurance Bureau, and submit the electronic files and scanned copies to the Joint Procurement Office by the system.
There was also news in the industry before that, the fifth batch of centralized procurement will be carried out in May-June.
01 Jicai has tilted injection
01 Jicai has tilted injection According to the incomplete statistics of the E medicine manager, 3 of 37 varieties have been reviewed, 4 of 8 varieties have been reviewed, 5 of 8 varieties have been reviewed, 6 of 5 varieties have been reviewed, and 9 of 1 variety have been reviewed.
13 varieties have been reviewed.
There are 13 companies that have reviewed rivaroxaban tablets, 9 companies have reviewed esomeprazole sodium for injection, 6 companies have reviewed levofloxacin sodium chloride injection, ceftriaxone sodium for injection, ceftazidime for injection 5 reviews.
13 varieties have been reviewed.
There are 13 companies that have reviewed rivaroxaban tablets, 9 companies have reviewed esomeprazole sodium for injection, 6 companies have reviewed levofloxacin sodium chloride injection, ceftriaxone sodium for injection, ceftazidime for injection 5 reviews.
It can be seen from the list of the fifth batch that the national centralized procurement has gradually tilted towards the field of injections, with 30 injection formulations accounting for 50% of all varieties.
Compared with the fourth batch of centralized procurement a few months ago, there are only 8 types of injections, accounting for 19%.
Compared with the fourth batch of centralized procurement a few months ago, there are only 8 types of injections, accounting for 19%.
Among the types of injections, antibiotics account for a relatively high proportion, including cefuroxime, ceftriaxone, ceftazidime, ceftazolin, azithromycin, etc.
; oncology drugs include gemcitabine, paclitaxel, oxaliplatin, docetaxel, etc.
; and diabetes The drug saxagliptin, esomeprazole (esomeprazole) in the digestive field, budesonide inhalation in the respiratory field and other large varieties.
Tumor tumor tumor; oncology drugs include gemcitabine, paclitaxel, oxaliplatin, docetaxel, etc.
; and diabetes The drug saxagliptin, esomeprazole (esomeprazole) in the digestive field, budesonide inhalation in the respiratory field and other large varieties.
Data show that in 2019, China's injection drug market has exceeded 600 billion yuan.
From the first to fifth batch of centralized procurement varieties, with the in-depth evaluation of the consistency of injections, the main force of centralized procurement across the country will further tilt toward the varieties of injections.
From the first to fifth batch of centralized procurement varieties, with the in-depth evaluation of the consistency of injections, the main force of centralized procurement across the country will further tilt toward the varieties of injections.
02 Foreign-invested AZ is the most shortlisted, and domestic-funded leaders play the leading role
From the perspective of the original research companies involved, AstraZeneca is the foreign-funded company with the largest variety of finalists in this round, involving 6 products, esomeprazole (esomeprazole) injection, isosorbide mononitrate sustained-release and controlled-release Dosage form, saxagliptin oral constant-release dosage form, oral bicalutamide oral constant-release dosage form for injection, budesonide inhalation, and metoprolol oral regular-release dosage form are shortlisted.
Among them, esomeprazole (esomeprazole) injection has been evaluated by 8 companies in addition to the original research, including well-known domestic companies such as Chia Tai Tianqing, Haisco, Osaikon; Isosorbide mononitrate sustained release Controlled-release dosage forms have also been reviewed by five companies including Qilu and Lepu; the competition for oral regular-release dosage forms of saxagliptin is more intense, with Qilu, Zhengda Tianqing, Hausen, and Osaikang all eyeing them.
Among them, esomeprazole (esomeprazole) injection has been evaluated by 8 companies in addition to the original research, including well-known domestic companies such as Chia Tai Tianqing, Haisco, Osaikon; Isosorbide mononitrate sustained release Controlled-release dosage forms have also been reviewed by five companies including Qilu and Lepu; the competition for oral regular-release dosage forms of saxagliptin is more intense, with Qilu, Zhengda Tianqing, Hausen, and Osaikang all eyeing them.
The number of products shortlisted by Pfizer is second only to AstraZeneca, reaching five.
Contains azithromycin injection; fluconazole sodium chloride injection, glipizide sustained-release and controlled-release dosage form, linezolid glucose injection, and misoprostol oral regular-release dosage form.
Many products will face the impact of centralized procurement from Kelun, Hausen, Yangtze River and Renfu.
Contains azithromycin injection; fluconazole sodium chloride injection, glipizide sustained-release and controlled-release dosage form, linezolid glucose injection, and misoprostol oral regular-release dosage form.
Many products will face the impact of centralized procurement from Kelun, Hausen, Yangtze River and Renfu.
GSK has three shortlisted products, dutasteride soft capsule, cefuroxime injection, and ceftazidime injection.
Among them, ceftazidime injection has been evaluated by Qilu, Hailing Chemical, Chengdu Beite, Yangtze River, and Hanmi Pharmaceutical Co.
, Ltd.
Among them, ceftazidime injection has been evaluated by Qilu, Hailing Chemical, Chengdu Beite, Yangtze River, and Hanmi Pharmaceutical Co.
, Ltd.
Sanofi's oncology product docetaxel injection and oxaliplatin injection are shortlisted, among which docetaxel injection faces the 5+1 competition of Hengrui, Yangtze River, Qilu, Zhengda Tianqing, and Huiyu.
Novartis, Boehringer Ingelheim, Fresenius Kabi and other foreign companies have two products shortlisted; Bayer and Daiichi Sankyo also each have one product shortlisted.
Novartis, Boehringer Ingelheim, Fresenius Kabi and other foreign companies have two products shortlisted; Bayer and Daiichi Sankyo also each have one product shortlisted.
In the past four batches and five rounds of centralized procurement, the original research pharmaceutical companies performed differently, but mainly focused on maintaining the original price system.
However, there are also companies that choose to directly compete with domestic generic drug companies and drastically cut prices.
For example, AstraZeneca’s Iressa in 4+7 volume procurement, Bayer’s Bayer in the second batch of centralized procurement, the fourth batch Propofol medium/long-chain fat emulsion injection from Fresenius Kabi in the collection.
However, there are also companies that choose to directly compete with domestic generic drug companies and drastically cut prices.
For example, AstraZeneca’s Iressa in 4+7 volume procurement, Bayer’s Bayer in the second batch of centralized procurement, the fourth batch Propofol medium/long-chain fat emulsion injection from Fresenius Kabi in the collection.
In terms of domestic pharmaceutical companies, China Biopharmaceutical's Chia Tai Tianqing, Chia Tai Fenghai, Beijing Tide and other products have accumulated more than 10 shortlisted products.
They are still the "big players" in this centralized procurement, followed by domestic generic drug giants Qilu, Yangtze River was also shortlisted for 9 products.
As the domestic infusion leader, Kelun has 8 injection products entering the market this time; traditional major manufacturers such as Hengrui, CSPC, Xinlitai, and Haisco have 3 products entering.
They are still the "big players" in this centralized procurement, followed by domestic generic drug giants Qilu, Yangtze River was also shortlisted for 9 products.
As the domestic infusion leader, Kelun has 8 injection products entering the market this time; traditional major manufacturers such as Hengrui, CSPC, Xinlitai, and Haisco have 3 products entering.
Judging from the results of the previous rounds of centralized procurement, drug prices fell by more than 50% on average, and the highest drop was more than 90%.
After this time, the market structure of a large number of varieties will change.
After this time, the market structure of a large number of varieties will change.
03Four major cephalosporin antibiotics in the list of basic medicines
03Four major cephalosporin antibiotics in the list of basic medicines In the current base drug list, there are a total of four cephalosporin antibiotic products for injection-cefazolin injection, cefuroxime sodium injection, ceftriaxone injection, and ceftazidime injection.
No one is spared in the fifth batch of collective procurement reports.
No one is spared in the fifth batch of collective procurement reports.
Ceftazidime injection and ceftriaxone injection have each entered the market with 6 companies.
Six companies including GSK, Qilu, Yangtze River, Hailing Chemical, Chengdu Beite, and Hanmi Pharmaceutical Co.
, Ltd.
compete for ceftazidime injection; Roche, Qilu, CSPC, Kelun, Jincheng Jinsu, and Runze will be on the ceftriaxone injection track A showdown.
Six companies including GSK, Qilu, Yangtze River, Hailing Chemical, Chengdu Beite, and Hanmi Pharmaceutical Co.
, Ltd.
compete for ceftazidime injection; Roche, Qilu, CSPC, Kelun, Jincheng Jinsu, and Runze will be on the ceftriaxone injection track A showdown.
The competitive landscape of cefuroxime injection is relatively sluggish, and it is in the three-part world of GSK, Whitison, and Runze Pharmaceutical.
On January 21 this year, Cefazolin for injection has just ushered in the first over-reviewed company, Jincheng Pharmaceutical .
Data show that the sales of cefazolin for injection in 2020 will be nearly 4 billion yuan.
Medicine Medicine MedicineData show that the sales of cefazolin for injection in 2020 will be nearly 4 billion yuan.
According to NMPA data, there are currently 16 cephalosporin products in China that have approved generic drugs.
Among the first four batches of centralized procurement, 7 products have been included in centralized procurement.
Among the 9 varieties not included in the collection, there are 8 injection varieties.
The blockbuster cephalosporin products included in the four basic medicines in the centralized procurement in one breath have a large variety with billions of sales.
After entering the centralized procurement, the market may usher in a wave of increased volume.
Among the first four batches of centralized procurement, 7 products have been included in centralized procurement.
Among the 9 varieties not included in the collection, there are 8 injection varieties.
The blockbuster cephalosporin products included in the four basic medicines in the centralized procurement in one breath have a large variety with billions of sales.
After entering the centralized procurement, the market may usher in a wave of increased volume.
04 Biosimilar drugs, Chinese medicine suspended
04 Biosimilar drugs, Chinese medicine suspended Judging from the fifth batch of centralized procurement catalogs, insulin, biosimilar drugs, and proprietary Chinese medicines that the industry continues to pay attention to are still not involved, which has made many companies let go of their suspicions.
Enterprise business enterprise However, judging from the "Opinions on Promoting the Normalized and Institutionalized Development of Centralized and Volume pharmnet.
com.
cn/news/yyzb/" target="_blank">Procurement of Drugs" issued by the State Council in January this year , the document proposes that unreviewed varieties, proprietary Chinese medicines, and biosimilars will be included in centralized drug procurement.
pharmnet. com.
cn/news/yyzb/" target="_blank">Procurement of Drugs" issued by the State Council in January this year , the document proposes that unreviewed varieties, proprietary Chinese medicines, and biosimilars will be included in centralized drug procurement.
com.
cn/news/yyzb/" target="_blank">Procurementpharmnet.
com.
cn/news/yyzb/" target="_blank"> Purchasing Procurement
In addition, on March 5th, the National Medical Insurance Bureau and the Department of Recruitment and Procurement and representatives of 11 provinces and cities including Tianjin, Shanghai, Chongqing and other joint procurement offices organized a drug centralized procurement work conference in Nanjing to study and carry out special drug procurement and study national procurement products with large quantities.
After the expiration, the contract renewal work will improve the selection rules of the national drug collection plan.
After the expiration, the contract renewal work will improve the selection rules of the national drug collection plan.
According to the normalized deployment of "centralized procurement twice a year", although biosimilar drugs and proprietary Chinese medicines have not yet appeared in the fifth batch of centralized procurement, whether it is the information released by the medical insurance bureau’s symposium or the normalized collection of the State Council From the perspective of opinions, it will be sooner or later that these types of products will be included in centralized procurement.
